Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
- Response deadline
- Oct 30, 2026 Due in 74 days
- Date posted
- Aug 17, 2026
- Source
- Open notice
Description
BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods. Mandatory Qualification Requirements: To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by: 1. Holding a U.S. influenza vaccine license; or 2. Have developed an influenza vaccine as evidenced by: a. Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine Please see full solicitation details and proposal submission instructions detailed in attachments 01-19 of this notice.
Classifications
Documents (19)
- 18-75A50126R00001_RFP Att 18 BCP SCP Continuity Plans.pdf.pdf75 KBNot yet available
- 09-75A50126R00001_RFP Att 9 ACH Vendor Misc Payment Enrollment Form.docx.docx61 KBNot yet available
- 04-75A50126R00001_RFP Att 3 Vendor Production Facilities.xlsx.xlsx25 KBNot yet available
- 16-75A50126R00001_RFP Att 16 Bill of Materials (BOM) Template.xlsx.xlsx93 KBNot yet available
- 11-75A50126R00001_RFP Att 11 SF LLL Disclosure of Lobbying Activities Form Instructions.pdf.pdf312 KBNot yet available
- 03-75A0126R00001_RFP Att 2 ASPR Security Requirements.pdf.pdf118 KBNot yet available
- 08-75A50126R00001_ RFP Att 8 Summary of Related Activities.docx.docx36 KBNot yet available
- 10-75A50126R00001_RFP Att 10 SF LLL Disclosure of Lobbying Activities Form.pdf.pdf89 KBNot yet available
- 15-75A50126R00001_RFP Att 15 Contractor Questions.xlsx.xlsx20 KBNot yet available
- 17-75A50126R00001_RFP Att 17 Manufacturing Plan.pdf.pdf60 KBNot yet available
- 06-75A50126R00001_RFP Att 5 BARDA Dose Tracker Template.xlsx.xlsx115 KBNot yet available
- 12-75A50126R00001_RFP Att 12 HHS Subcontracting Plan Template.docx.docx80 KBNot yet available
- 05-75A50126R00001_RFP Att 4 Agent Request Form.docx.docx40 KBNot yet available
- 19_75A50126R0001_RFP Att 19 Surge Manufacturing and Supply Chain Readiness Assessment.pdf.pdf41 KBNot yet available
- 02-75A50126R00001_RFP Att 1 Prod Handling Guidance Don Nat.pdf.pdf62 KBNot yet available
- 07-75A50126R00001_RFP Att 7 Breakdown of Proposed Costs.xlsx.xlsx23 KBNot yet available
- 14-75A50126R00001_RFP Att 14 Past Perfomance Questionnaire Template.docx.docx184 KBNot yet available
- 01-75A50126R00001_RFP_Final.pdf.pdf1.2 MBNot yet available
- 13-75A50126R00001_RFP Att 13 Risk Mitigation Plan Matrix Template.docx.docx31 KBNot yet available
Contacts
Similar contracts
- Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract
- Sole Source - Production of ChAdOx-1 and MVA expressing mouse gp70OxfordshireDue Aug 24, 2026
- Validation and Optimization of ONE-STEP Tagging in Human induced Pluripotent Stem CellsMarylandDue Aug 21, 2026
- Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
- Q301--Zymo Epigenome Sequencing ServicesDue Aug 21, 2026
- Future Program: Intrinsic Market Resilience (IMR)Due Aug 31, 2026